231 related articles for article (PubMed ID: 17404291)
21. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
[TBL] [Abstract][Full Text] [Related]
22. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
24. IL-12 administered in vivo to young and aged mice. Discrepancy between the effects on tumor growth in vivo and cytotoxic T lymphocyte generation ex vivo: dependence on IFN-gamma.
Horvath-Arcidiacono JA; Mostowski HS; Bloom ET
Int Immunol; 1996 May; 8(5):661-73. PubMed ID: 8671653
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of IFN-lambda in murine tumor models.
Sato A; Ohtsuki M; Hata M; Kobayashi E; Murakami T
J Immunol; 2006 Jun; 176(12):7686-94. PubMed ID: 16751416
[TBL] [Abstract][Full Text] [Related]
26. Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells.
Zier KS; Gansbacher B
Eur J Cancer; 1996 Jul; 32A(8):1408-12. PubMed ID: 8869107
[TBL] [Abstract][Full Text] [Related]
27. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
28. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells.
Bohn E; Autenrieth IB
J Immunol; 1996 Feb; 156(4):1458-68. PubMed ID: 8568248
[TBL] [Abstract][Full Text] [Related]
29. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
30. Generation of a systemic antitumor response with regional intratumoral injections of interferon gamma retroviral vector.
Karavodin LM; Robbins J; Chong K; Hsu D; Ibanez C; Mento S; Jolly D; Fong TC
Hum Gene Ther; 1998 Oct; 9(15):2231-41. PubMed ID: 9794207
[TBL] [Abstract][Full Text] [Related]
31. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
32. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
33. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
Eguchi J; Hiroishi K; Ishii S; Mitamura K
Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
[TBL] [Abstract][Full Text] [Related]
34. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals.
Chiyo M; Shimozato O; Yu L; Kawamura K; Iizasa T; Fujisawa T; Tagawa M
Int J Cancer; 2005 Jun; 115(3):437-42. PubMed ID: 15688376
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-12 induces cytotoxic NK1+ alpha beta T cells in the lungs of euthymic and athymic mice.
Anzai R; Seki S; Ogasawara K; Hashimoto W; Sugiura K; Sato M; Kumagai K; Takeda K
Immunology; 1996 May; 88(1):82-9. PubMed ID: 8707355
[TBL] [Abstract][Full Text] [Related]
36. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
Baxevanis CN; Gritzapis AD; Papamichail M
J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
[TBL] [Abstract][Full Text] [Related]
37. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
38. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
Hirahara N; Nio Y; Sasaki S; Minari Y; Takamura M; Iguchi C; Dong M; Yamasawa K; Tamura K
Oncology; 2001; 61(1):79-89. PubMed ID: 11474253
[TBL] [Abstract][Full Text] [Related]
39. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA.
Yamanaka R; Yajima N; Tsuchiya N; Honma J; Tanaka R; Ramsey J; Blaese M; Xanthopoulos KG
J Neurosurg; 2002 Nov; 97(5):1184-90. PubMed ID: 12450042
[TBL] [Abstract][Full Text] [Related]
40. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration.
Orange JS; Wang B; Terhorst C; Biron CA
J Exp Med; 1995 Oct; 182(4):1045-56. PubMed ID: 7561678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
